Lutetium Lu-177 dotatate
SSTR-targeted radiopeptide
Also Lutathera, Lu-177 dotatate, 177Lu-DOTATATE, Lutetium-177 dotatate, Lu177 dotatate, 177Lu-DOTA-TATE
- Evidence
- AStrong human evidence
- FDA status
- FDA approvedas of 2026-10-26
- Route
- Intravenous
- Studies cited
- 1 human0 animal or cell
It is a radioactive drug given through a vein to treat certain gut tumors. A trial of 229 patients showed it cut the risk of the tumor growing by 79%.
Sold for
Lutathera is discussed in oncology circles, with no wellness market, as the first radioactive peptide drug to win FDA approval and the model for the targeted radioligand drugs that followed.
Studies say
A 229-patient randomized trial showed a 79 percent reduction in progression or death versus octreotide, which supports an A grade for its approved use.
Why grade A. Approval rests on NETTER-1, a randomized open-label phase 3 trial in 229 patients with progressive midgut neuroendocrine tumors, which showed a large improvement in progression-free survival over high-dose octreotide, supported by a Dutch single-center series of more than 1,200 patients. The remaining gap is overall survival, where the final NETTER-1 analysis showed no statistically significant difference. 12
FDA. Approved. Lutetium Lu-177 dotatate (Lutathera, Novartis) was approved in January 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors in adults, and in 2024 the indication was extended to patients aged 12 and older. 2
Written from 2 cited sources. Fact-checked 2026-10-27: 16 claims checked, 3 corrected. Last refreshed 2026-10-27. Not physician reviewed.
What this means for you
- What people take it for
- Treating certain gut tumors
- Can a US doctor prescribe it?
- Yes, FDA approved for certain gut and pancreas tumors.
- Properly tested in people?
- Yes, in a controlled trial of 229 patients.
Evidence checklist
- Randomised controlled trial NETTER-1, open-label vs high-dose octreotideyes
- Human study over 100 people NETTER-1, 229; Dutch series 1,214yes
- More than one research group Pivotal trial plus one single-centre seriesno
- Clinical outcomes, not surrogate markers Progression-free survival; no clear survival gainyes
- Human safety data beyond case reports Marrow, kidney and leukemia risks documentedyes
Drawn from the cited studies below. A dash means the sources give no information.
What it is
Lutetium Lu-177 dotatate is a radiopharmaceutical. The peptide part, dotatate (DOTA-Tyr3-octreotate), is a somatostatin analog related to octreotide that binds tightly to somatostatin receptor type 2. The DOTA cage holds a lutetium-177 atom, a radioactive metal that emits beta particles with a half-life of about 6.6 days. The combination delivers radiation directly to cells carrying the receptor. The approach is called peptide receptor radionuclide therapy. 2
It is given as an intravenous infusion in a nuclear medicine unit, with an amino acid solution infused alongside to protect the kidneys. The approved indication is somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut tumors, in adults and, since 2024, in adolescents. 2
How it works
Neuroendocrine tumor cells express far more somatostatin receptor type 2 than normal tissue. Dotatate binds the receptor and is pulled inside the cell, carrying lutetium-177 with it. The beta particles travel only about two millimeters in tissue, so the radiation damages the DNA of the tumor cell and its near neighbors while sparing most surrounding organs. Patients are typically imaged first with a gallium-68 or copper-64 somatostatin tracer to confirm the tumors take up the peptide. 2
What human research shows
NETTER-1 randomized 229 patients with advanced midgut neuroendocrine tumors that had progressed on standard-dose octreotide to lutetium Lu-177 dotatate plus octreotide or to high-dose octreotide alone. At the primary analysis, estimated progression-free survival at 20 months was 65.2 percent in the radioligand arm versus 10.8 percent in the control arm, a 79 percent reduction in the risk of progression or death. Response rates were 18 percent versus 3 percent. 1
The label also summarizes a Dutch single-arm series of 1,214 patients treated at Erasmus MC, which contributed safety and response data across GEP-NET types, The 2024 extension to patients aged 12 and older was not based on a separate efficacy trial: the label extrapolates from NETTER-1 in adults, supported by safety, pharmacokinetic and radiation-dose data in a small number of adolescents, four of whom had GEP-NETs. 2
| Study | Model | Finding |
|---|---|---|
| NETTER-1 (Strosberg 2017) | Humans, n=229 with progressive midgut NETs, randomized open-label phase 3 | Progression-free survival at 20 months was 65 percent versus 11 percent on high-dose octreotide; hazard ratio 0.21. 1 |
| Lutathera prescribing information | FDA label including the Erasmus MC series (n=1,214) and pediatric pharmacokinetic and safety data | Response and safety data across GEP-NET subtypes; myelosuppression, secondary myeloid cancers, and kidney toxicity as key warnings. 2 |
Safety
Common side effects in NETTER-1 were nausea and vomiting (partly from the protective amino acid infusion), fatigue, and lowered blood counts. Grade 3 or 4 drops in white cells, platelets, or lymphocytes occurred in a minority of patients. Because the radiation also reaches bone marrow and kidneys, the label warns of myelosuppression, secondary leukemia and myelodysplastic syndrome (seen in about 2 percent of patients in long-term follow-up), and kidney toxicity. 12
Hormonal crisis from sudden tumor hormone release, infertility, and harm to a fetus are also listed. Patients emit radiation for days after treatment and get instructions on limiting close contact. Long-term kidney and marrow outcomes beyond about five years are still being collected. 2
Questions for your clinician
- Does this treatment help people live longer, or mainly delay progression?
- How will my blood counts and kidney function be monitored?
- What radiation precautions apply to my family after each dose?
Questions people ask
Which patients receive lutetium Lu-177 dotatate?
Gastroenteropancreatic neuroendocrine tumors that show somatostatin receptors on imaging, in adults and patients aged 12 and older. 2
Is it chemotherapy?
No. It is a targeted radiation treatment: a somatostatin-like peptide carries a radioactive lutetium atom to the tumor cells, which are then damaged by beta radiation from within. 2
How well does it work?
In NETTER-1, 65 percent of patients were free of progression at 20 months versus 11 percent on high-dose octreotide. In the final overall survival analysis, 66 months after the primary analysis, there was no statistically significant difference between the arms. 12
What are the long-term risks?
Bone marrow damage, including a roughly 2 percent rate of secondary leukemia or myelodysplastic syndrome, and kidney injury. The amino acid infusion given with each dose is there to protect the kidneys. 2
Citations
- Strosberg 2017, NEJM: Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors (NETTER-1) doi.org
- Novartis: Lutathera US prescribing information novartis.com